posted on 2013-08-08, 00:00authored byJingrong Li, Nan Wu, Yuanxin Tian, Jiajie Zhang, Shuguang Wu
A series
of novel aminopyridyl/pyrazinyl-substituted spiro[indoline-3,4′-piperidine]-2-ones
were designed, synthesized, and tested in various in vitro/in vivo
pharmacological and antitumor assays. 6-[6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-pyridyl]-1′-methylspiro[indoline-3,4′-piperidine]-2-one
(compound 5b or SMU-B) was identified as
a potent, highly selective, well-tolerated, and orally efficacious
c-Met/ALK dual inhibitor, which showed pharmacodynamics effect by
inhibiting c-Met phosphorylation in vivo and significant tumor growth
inhibitions (>50%) in GTL-16 human gastric carcinoma xenograft
models.